Corrigendum

Corrigendum Corrigendum (727) Total Article Views Authors: Dupclay L, Eaddy M, Jackson J, Raju A, Shim A Published Date September 2012 Volume 2012:6 Pages 677 - 678 DOI: http://dx.doi.org/10.2147/PPA.S37120 Received: 17 August 2012 Accepted: Published: 24 September 2012 Dupclay L, Eaddy M, Jackson J, Raju A, Shim A. Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence. Patient Prefer Adherence. 2012;6:499–507. The following sentence on page 499 was incorrect in the published paper: In a total of 9266 matched patients (4633 participants in both cohorts), adherence was significantly higher in the RP cohort compared with patients in the non-RP cohort (medication possession ratio, RP 80% versus non-RP 73%; proportion of days covered, RP 76% versus non-RP 63%; both P < 0.001). The correct sentence should read: In a total of 9266 matched patients (4633 participants in both cohorts), adherence was significantly higher in the RP cohort compared with patients in the non-RP cohort (medication possession ratio, RP 80% versus non-RP 73%; proportion of days covered, RP 65% versus non-RP 63%; both P < 0.001). Also on page 504 the following sentence was incorrect in the published paper: With similar baseline adherence (medication possession ratio 82%), the post-index adherence was significantly higher in the RP cohort (patients who switched from valsartan-hydrochlorothiazide combination therapy without RP to valsartan-hydrochlorothiazide combination therapy with RP) compared with the non-RP cohort (valsartan-hydrochlorothiazide combination patients who did not switch to RP, medication possession ratio 80% for RP cohort versus 73% for the non-RP cohort; proportion of days covered 76% for RP group versus 63% for non-RP group; both P < 0.001, Table 2). The correct sentence should read: With similar baseline adherence (medication possession ratio 82%), the post-index adherence was significantly higher in the RP cohort (patients who switched from valsartan-hydrochlorothiazide combination therapy without RP to valsartan-hydrochlorothiazide combination therapy with RP) compared with the non-RP cohort (valsartan-hydrochlorothiazide combination patients who did not switch to RP, medication possession ratio 80% for RP cohort versus 73% for the non-RP cohort; proportion of days covered 65% for RP group versus 63% for non-RP group; both P < 0.001, Table 2). Read the original article Post to: Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter Other articles by Dr Michael Eaddy Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence Readers of this article also read: The cognitive impact of anticholinergics: A clinical review Morgellons disease: Analysis of a population with clinically confirmed microscopic subcutaneous fibers of unknown etiology Lyme disease: the next decade Improving patient–physician dialog: commentary on the results of the MS Choices survey A physiotherapy triage a